Schwartzberg, Lee

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.

Hochster, H. S., Hart, L. L., Ramanathan, R. K., Childs, B. H., Hainsworth, J. D., Cohn, A. L., Wong, L., Fehrenbacher, L., Abubakr, Y., Saif, M. W., et al. (2008) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 613

Phase III Study of Iniparib Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer

O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., et al. (2014) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesPARP inhibition in cancer therapy

Cited by 311

Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial

Graetz, I., McKillop, C. N., Stepanski, E., Vidal, G. A., Anderson, J. N., & Schwartzberg, L. S. (2018) · Journal of Cancer Survivorship

Mobile Health and mHealth ApplicationsMedication Adherence and Compliance

Cited by 106

TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.

Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., Wahner Hendrickson, A. E., Forero-Torres, A., Anders, C. K., Wulf, G. M., et al. (2018) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBreast Cancer Treatment Studies

Cited by 77

Managing hyperglycemia and rash associated with alpelisib: expert consensus recommendations using the Delphi technique

Gallagher, E. J., Moore, H., Lacouture, M. E., Dent, S. F., Farooki, A., Goncalves, M. D., Isaacs, C., Johnston, A., Juric, D., Quandt, Z., et al. (2024) · npj Breast Cancer

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 36

Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot study

Rugo, H., Forsythe, A., Flora, D., Glück, S., Grieve, S., Campden, R., Liu, R. J., Musat, M., Rege, J. M., Kaufman, P. A., et al. (2026) · ESMO Real World Data and Digital Oncology

Artificial Intelligence in Healthcare and EducationMeta-analysis and systematic reviews

Cited by 0